Reasonably, the treatment of a primary HCC model established using GSK 8612 (a highly selective TBK1 inhibitor) in mice with chronic liver inflammation significantly attenuated HCC progression in C57 BL/6 mice [13]. This evidence concerns the gene TBK1 and hepatocellular carcinoma.